l 753037 has been researched along with nitroblue tetrazolium in 1 studies
| Studies (l 753037) | Trials (l 753037) | Recent Studies (post-2010) (l 753037) | Studies (nitroblue tetrazolium) | Trials (nitroblue tetrazolium) | Recent Studies (post-2010) (nitroblue tetrazolium) |
|---|---|---|---|---|---|
| 18 | 1 | 1 | 2,315 | 17 | 92 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kamata, K; Kanie, N | 1 |
1 other study(ies) available for l 753037 and nitroblue tetrazolium
| Article | Year |
|---|---|
Effects of chronic administration of the novel endothelin antagonist J-104132 on endothelial dysfunction in streptozotocin-induced diabetic rat.
Topics: Acetylcholine; Administration, Oral; Animals; Blood Glucose; Cholesterol; Diabetes Mellitus, Experimental; Dose-Response Relationship, Drug; Drug Administration Schedule; Endothelin Receptor Antagonists; Endothelium, Vascular; In Vitro Techniques; Male; Membrane Transport Proteins; Muscle Relaxation; NADPH Dehydrogenase; NADPH Oxidases; Nitric Oxide Synthase; Nitric Oxide Synthase Type III; Nitroblue Tetrazolium; Nitroprusside; Oxidation-Reduction; Phosphoproteins; Pyridines; Rats; Rats, Wistar; Receptors, Endothelin; RNA, Messenger; Superoxides; Triglycerides | 2002 |